Serum and Urinary Interferon-Gamma-Inducible Protein 10 in Lupus Nephritis - PubMed (original) (raw)

. 2016 Nov;30(6):1135-1138.

doi: 10.1002/jcla.21993. Epub 2016 May 17.

Affiliations

Serum and Urinary Interferon-Gamma-Inducible Protein 10 in Lupus Nephritis

Ahmed El-Gohary et al. J Clin Lab Anal. 2016 Nov.

Abstract

Background: Lupus nephritis is a serious manifestation of systemic lupus erythematosus (SLE). The objective of this study was to identify the sensitivity, specificity, and cut-off values of IP-10 in the serum and urine of patients with lupus nephritis compared to renal biopsy, albumin/creatinine ratio, and serum anti-dsDNA.

Methods: Thirty female SLE patients were included. SLEDAI was calculated and blood and urine samples were collected. Patients were divided into 10 SLE patients with renal involvement (six active and four inactive), 10 active SLE, and 10 inactive SLE patients. Ten age-matched healthy (control) were included. Serum and urinary levels of IP-10 were measured by ELISA. Anti-dsDNA, urine albumin/creatinine ratio were performed.

Results: Serum and urinary IP-10 in active SLE patients had significantly increased levels as compared to inactive SLE patients (P = 0.015, P = 0.033, respectively). However, there was no difference in serum and urinary levels between active renal and active non-renal patients. Albumin/creatinine ratio is a better marker in differentiating between lupus nephritis and SLE with no renal involvement. Any of serum and urinary IP-10, albumin/creatinine ratio, and anti-dsDNA did not correlate with the class of lupus nephritis in renal biopsy.

Conclusion: Urinary and serum IP-10 are useful markers of lupus activity, but not indicative of renal activity. Albumin/creatinine ratio is superior in identifying lupus nephritis and renal activity.

Keywords: IP-10; albumin/creatinine ratio; lupus nephritis; systemic lupus erythematosus.

© 2016 Wiley Periodicals, Inc.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no financial or non‐financial conflicts of interest related to the subject matter or materials discussed in the article.

Figures

Figure 1

Figure 1

ROC

curve showing the ability of (a) serum and urinary

IP

‐10 in differentiating

SLE

patients from Healthy controls (b) serum

IP

‐10 in differentiating active from inactive

SLE

.

References

    1. Mok CC, Tang SS, To CH, et al. Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups. Arthritis Rheum 2005;52:2774–2782. - PubMed
    1. Mok CC. Prognostic factors in lupus nephritis. Lupus 2005;14:39–44. - PubMed
    1. Mok CC. Therapeutic options for resistant Lupus nephritis. Semin Arthritis Rheum 2006;36:71–81. - PubMed
    1. Mok CC. Biomarkers for Lupus Nephritis: a Critical Appraisal. J Biomed Biotechnol 2010;2010:638413. - PMC - PubMed
    1. Abujam B, Cheekatla SS, Aggarwal A. Urinary CXCL‐10/IP‐10 and MCP‐1 as markers to assess activity of lupus nephritis. Lupus 2013;22:614–623. - PubMed

MeSH terms

Substances

LinkOut - more resources